Global X S&P Biotech ETF
Global X · S&P Biotechnology Select Industry Index · Since 2015
Annual fee
0.45%
$45/year per $10,000
Fund size
$40M
AUD
Dividend yield
0.8%
Annually · approx. as at Q2 2026
Holdings
143
companies
Dividend yield is a trailing distribution figure. Past performance is not a reliable indicator of future returns.
Next estimated distribution: ~December 2026 (estimated, not guaranteed; confirm with the fund manager). Distribution calendar →
CURE is a global healthcare ETF. Healthcare is one of the relatively defensive sectors, demand for medicines and medical services is less sensitive to economic cycles. CURE provides global healthcare sector exposure.
Based on publicly available fund data. Not a recommendation to buy or sell.
Strengths
Watch out for
| Company | Weight |
|---|---|
| Revolution Medic | 1.8% |
| Travere Therapeu | 1.7% |
| Tg Therapeutics | 1.7% |
| Alkermes Plc | 1.6% |
| Arrowhead Pharma | 1.6% |
| Cytokinetics Inc. | 1.4% |
| Celcuity Inc. | 1.4% |
| Exelixis Inc. | 1.4% |
| Neurocrine Biosc | 1.4% |
| Madrigal Pharmac | 1.4% |
See how CURE combines with your other ETFs: Stock X-Ray →
| Sector | Weight |
|---|---|
| Health Care | 99.8% |
| Country | Weight |
|---|---|
| United States | 96.7% |
| Netherlands | 1.1% |
| Switzerland | 1.1% |
| Ireland | 1.1% |
Historical returns
Past performance is not a reliable indicator of future returns.
Data as at Q2 2026. Past performance is not a reliable indicator of future returns. Figures are approximate total returns in AUD including distributions. Source: fund manager fact sheets.
Compare CURE with similar ETFs
Side-by-side fees, holdings overlap and performance.
Find near-twins of CURE →General information only, not financial advice. ETFLens does not hold an AFSL. Always read the relevant PDS and consider seeking advice from a licensed financial adviser.
CURE is a global healthcare ETF.
CURE's annual management fee is 0.45% p.a. ($45 per $10,000 invested).
CURE pays distributions annually. Distributions are not guaranteed and will vary.